United States securities and exchange commission logo

                             May 20, 2022

       Alfred Altomari
       Chief Executive Officer
       Agile Therapeutics, Inc.
       500 College Road East, Suite 310
       Princeton, New Jersey 08540

                                                        Re: Agile Therapeutics,
Statement on Form S-1
                                                            Filed May 13, 2022
                                                            File No. 333-264960

       Dear Mr. Altomari:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       Cover Page

   1.                                                   When available, please
revise your prospectus cover page to clarify the number of shares
                                                        and warrants being
   2.                                                   Please revise your
prospectus cover page to disclose the date on which the offering will
                                                        terminate. For
guidance, please refer to Item 501(b)(8)(iii) of Regulation S-K.
       Use of Proceeds, page 14

   3.                                                   Please revise your Use
of Proceeds section to show how the amount of proceeds will be
                                                        allocated assuming
different amounts of proceeds raised and the number of shares sold,
                                                        for example 100%, 75%,
50% and 25% of the shares offered for sale in this offering.
 Alfred Altomari
Agile Therapeutics, Inc.
May 20, 2022
Page 2

4.    Please file the placement agent agreement as an exhibit to your
registration statement or
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       Please contact Alan Campbell at 202-551-4224 or Celeste Murphy at
202-551-3257 with
any questions.

FirstName LastNameAlfred Altomari
                                                           Division of
Corporation Finance
Comapany NameAgile Therapeutics, Inc.
                                                           Office of Life
May 20, 2022 Page 2
cc:       Bryan S. Keighery
FirstName LastName